Recurrent heartburn after laparoscopic fundoplication is not always recurrent reflux.
BACKGROUND
A small cohort of patients present after antireflux surgery complaining of recurrent heartburn. Many of these patients have been empirically recommenced on proton pump inhibitors.


OBJECTIVE
The aim of this study was to determine whether patients with symptoms that suggest recurrent reflux had objective evidence of reflux, and to determine predictors of recurrent reflux.


METHODS
We identified all patients from an existing database who had undergone pH monitoring for "recurrent heartburn" after fundoplication. These patients were then cross-referenced to another database, which recorded the outcomes for patients who had undergone a laparoscopic fundoplication. Patients complaining of dysphagia or other problems without heartburn were excluded from analysis.


RESULTS
Seventy-six patients were identified who met the inclusion criteria. Fifty-six (74%) of these had a normal 24-h pH study. Thirty-five patients (63%) with a normal pH study were on medication for heartburn at the time of referral. Three factors were found to be associated with an abnormal 24-h pH study: a partial fundoplication (P = 0.039), onset of symptoms 6 months or more after surgery (P < 0.001), and a good symptom response when antireflux medication was recommenced (P = 0.015).


CONCLUSIONS
Not all patients complaining of recurrent heartburn after fundoplication have evidence of abnormal reflux. Objective evidence of abnormal esophageal acid exposure should be confirmed before recommencing antireflux medication.
Thompson
Sarah K
SK
Department of Surgery, University of Adelaide, Level 5, Eleanor Harrald Building, Royal Adelaide Hospital, Adelaide, South Australia 5000, Australia. sarah.thompson@adelaide.edu.au
Jamieson
Glyn G
GG
Myers
Jennifer C
JC
Chin
Kin-Fah
KF
Watson
David I
DI
Devitt
Peter G
PG
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000863:Antacids / Q000627:therapeutic use; D015331:Cohort Studies; D003680:Deglutition Disorders / Q000175:diagnosis; D050782:Esophageal pH Monitoring; D004941:Esophagitis / Q000175:diagnosis; D004945:Esophagoscopy; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D018662:Fundoplication / Q000009:adverse effects / Q000379:methods*; D005764:Gastroesophageal Reflux / Q000175:diagnosis / Q000601:surgery*; D006356:Heartburn / Q000175:diagnosis / Q000209:etiology*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D010535:Laparoscopy; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D054328:Proton Pump Inhibitors; D012008:Recurrence; D016896:Treatment Outcome
D000863:Antacids; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors